AR078166A1 - (heteroarilmetil) tiohidantoinas sustituidas - Google Patents
(heteroarilmetil) tiohidantoinas sustituidasInfo
- Publication number
- AR078166A1 AR078166A1 ARP100103311A ARP100103311A AR078166A1 AR 078166 A1 AR078166 A1 AR 078166A1 AR P100103311 A ARP100103311 A AR P100103311A AR P100103311 A ARP100103311 A AR P100103311A AR 078166 A1 AR078166 A1 AR 078166A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- methyl
- substituted
- fluorine
- trifluoromethyl
- Prior art date
Links
- -1 tetrahydro-2H-pyranyl Chemical group 0.000 abstract 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 5
- 239000011737 fluorine Chemical group 0.000 abstract 5
- 229910052731 fluorine Inorganic materials 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000005959 diazepanyl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 2
- 125000002632 imidazolidinyl group Chemical group 0.000 abstract 2
- 125000002757 morpholinyl group Chemical group 0.000 abstract 2
- 125000005961 oxazepanyl group Chemical group 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 125000004193 piperazinyl group Chemical group 0.000 abstract 2
- 125000003386 piperidinyl group Chemical group 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 2
- 125000001422 pyrrolinyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Chemical class 0.000 abstract 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- OMRRUNXAWXNVFW-UHFFFAOYSA-N fluoridochlorine Chemical compound ClF OMRRUNXAWXNVFW-UHFFFAOYSA-N 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Métodos para su preparacion, su uso para el tratamiento y/o profilaxis de enfermedades, y su uso para la preparacion de medicamentos para el tratamiento y/o profilaxis de enfermedades, en particular del cáncer de prostata. Reivindicacion 1: Un compuesto caracterizado porque es de formula general (1) donde: X significa nitrogeno o un grupo CH, R1 significa un grupo C1-3-alquilo fluorado, un grupo C1-4-alcoxi opcionalmente fluorado, un grupo C2-4-alcoxi opcionalmente sustituido, el cual está sustituido con uno o dos o tres sustituyentes seleccionados entre el grupo que consiste en metilo, fluor y trifluorometilo, un grupo metoxi-C2-4-alcoxi opcionalmente sustituido, el cual está sustituido con uno o dos o tres sustituyentes seleccionados entre el grupo que consiste en metilo, fluor y trifluorometilo, un grupo (tetrahidro-2H-piranil))oxi-, un grupo heteroaromático de cinco miembros opcionalmente sustituido seleccionado entre el grupo que consiste en pirrolilo, pirazolilo, imidazolilo, triazolilo, tetrazolilo, tienilo, oxazolilo, isoxazolilo, furanilo, tiazolilo, oxadiazolilo, donde el grupo heteroaromático de cinco miembros se sustituye con uno o dos sustituyentes seleccionados entre el grupo que consiste en metilo, trifluorometilo, metoxi-, trifluorometoxi-, cloro, fluor, hidroxi, amino, hidroximetilo y ciano, un grupo heterocíclico de cinco, seis, o siete miembros opcionalmente sustituido seleccionado entre pirrolidinilo, piperidinilo, piperazinilo, morfolinilo, tiomorfolinilo, diazepanilo, tetrahidrofuranilo, pirrolinilo, imidazolidinilo y oxazepanilo, donde el grupo heterocíclico de cinco, seis, o siete miembros se sustituye con uno o dos o tres sustituyentes seleccionados entre el grupo que consiste en metilo, trifluorometilo, hidroximetilo, fluor, hidroxi, oxo, oxido, imino, C1-4-alquilimino, metilimino, cianoimino, y ciano; un residuo -O(CH2)-Y donde n = 2 o n = 3, e Y es un grupo heterocíclico de cinco, seis, o siete miembros opcionalmente sustituido seleccionado entre pirrolidinilo, piperidinilo, piperazinilo, morfolinilo, tiomorfolinilo, diazepanilo, tetrahidrofuranilo, pirrolinilo, imidazolidinilo y oxazepanilo, donde el grupo heterocíclico de cinco, seis, o siete miembros se sustituye con uno o dos sustituyentes seleccionados entre el grupo que consiste en metilo, trifluorometilo, hidroximetilo, fluor, hidroxi, oxo, oxido, imino, C1-4-alquilimino-, y ciano; o un residuo -N=S(=O)R3R4, donde R3 representa un grupo arilo o un grupo fenilo y R4 representa un grupo C1-4-alquilo o metilo; R2 significa hidrogeno, metilo, amino o fluor, o sus sales, solvatos o sales de solvatos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09075421 | 2009-09-11 | ||
| EP10075069 | 2010-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078166A1 true AR078166A1 (es) | 2011-10-19 |
Family
ID=42782041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103311A AR078166A1 (es) | 2009-09-11 | 2010-09-10 | (heteroarilmetil) tiohidantoinas sustituidas |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20120251551A1 (es) |
| EP (1) | EP2475653A1 (es) |
| JP (1) | JP2013504523A (es) |
| KR (1) | KR20120065396A (es) |
| CN (1) | CN102639523A (es) |
| AR (1) | AR078166A1 (es) |
| AU (1) | AU2010294588A1 (es) |
| BR (1) | BR112012005526A2 (es) |
| CA (1) | CA2773591A1 (es) |
| CL (1) | CL2012000623A1 (es) |
| CO (1) | CO6511228A2 (es) |
| CR (1) | CR20120113A (es) |
| CU (1) | CU20120042A7 (es) |
| DO (1) | DOP2012000063A (es) |
| EA (1) | EA201200473A1 (es) |
| EC (1) | ECSP12011716A (es) |
| IL (1) | IL218390A0 (es) |
| IN (1) | IN2012DN02081A (es) |
| MA (1) | MA33566B1 (es) |
| MX (1) | MX2012002977A (es) |
| NZ (1) | NZ598643A (es) |
| PE (1) | PE20121180A1 (es) |
| PH (1) | PH12012500497A1 (es) |
| SG (1) | SG178919A1 (es) |
| TN (1) | TN2012000108A1 (es) |
| TW (1) | TW201111378A (es) |
| UY (1) | UY32882A (es) |
| WO (1) | WO2011029537A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2733221T3 (es) | 2010-02-17 | 2019-11-28 | Takeda Pharmaceuticals Co | Compuesto heterocíclico |
| EP2576536B1 (en) * | 2010-06-01 | 2016-09-14 | The University of Queensland | Haematopoietic-prostaglandin d2 synthase inhibitors |
| SI2794627T1 (sl) | 2011-12-22 | 2019-02-28 | Alios Biopharma, Inc. | Substituirani nukleozidi, nukleotidi in njihovi analogi |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| TW201408688A (zh) | 2012-05-25 | 2014-03-01 | Janssen R & D Ireland | 尿嘧啶基螺氧環丁烷（ｓｐｉｒｏｏｘｅｔａｎｅ）核苷類 |
| TW201418243A (zh) | 2012-11-15 | 2014-05-16 | Bayer Pharma AG | 含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物 |
| GEP201706757B (en) | 2012-12-21 | 2017-10-25 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| WO2014153280A1 (en) * | 2013-03-22 | 2014-09-25 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| CN104341351B (zh) * | 2013-07-30 | 2018-02-06 | 北京海美源医药科技有限公司 | 一种二芳基硫代乙内酰脲衍生物及其应用 |
| RS63939B1 (sr) * | 2013-12-11 | 2023-02-28 | Celgene Quanticel Research Inc | Inhibitori lizin specifične demetilaze-1 |
| EP3083596A1 (en) | 2013-12-18 | 2016-10-26 | Basf Se | Azole compounds carrying an imine-derived substituent |
| US9682960B2 (en) | 2013-12-19 | 2017-06-20 | Endorecherche, Inc. | Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety |
| CN103896847B (zh) * | 2014-04-09 | 2016-01-20 | 沈江 | 一种非甾体类抗雄激素化合物及其制备方法和应用 |
| ES2749186T3 (es) | 2014-05-07 | 2020-03-19 | Evotec Int Gmbh | Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas |
| TWI656121B (zh) | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| CN106187905B (zh) * | 2015-05-05 | 2020-02-21 | 北京海步医药科技股份有限公司 | 丁鲁他胺的结晶形式及其制备方法 |
| CA3001085A1 (en) | 2015-10-08 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Novel modified macrocyclic compounds |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| EP3601236A1 (en) | 2017-03-28 | 2020-02-05 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
| US11254690B2 (en) | 2017-03-28 | 2022-02-22 | Bayer Pharma Aktiengesellschaft | PTEFb inhibiting macrocyclic compounds |
| TW201900604A (zh) | 2017-05-18 | 2019-01-01 | 印度商Ｐｉ工業公司 | 新穎的脒化合物 |
| CA3090843A1 (en) | 2018-02-13 | 2019-08-22 | Bayer Aktiengesellschaft | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma |
| CA3132963A1 (en) * | 2019-04-11 | 2020-10-15 | University Of Miami | Improved inhibitors of the notch transcriptional activation complex and methods for use of the same |
| US20230135524A1 (en) * | 2020-01-21 | 2023-05-04 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Aryl hydantoin heterocycles and methods of use |
| WO2022206742A1 (zh) * | 2021-03-30 | 2022-10-06 | 苏州开拓药业股份有限公司 | 一种一步法合成乙内酰硫脲衍生物的方法 |
| WO2025103470A1 (zh) * | 2023-11-17 | 2025-05-22 | 中国药科大学 | 作为雄激素受体(ar)拮抗剂的化合物及其应用 |
| CN120309588B (zh) * | 2025-06-10 | 2025-08-12 | 上海健康医学院 | 一种具有雄激素受体和组蛋白去乙酰化酶6双重抑制作用的乙内酰硫脲类化合物及其用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2671348B1 (fr) | 1991-01-09 | 1993-03-26 | Roussel Uclaf | Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant. |
| USRE35956E (en) | 1991-01-09 | 1998-11-10 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
| FR2693461B1 (fr) | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| US5411981A (en) | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
| FR2694290B1 (fr) | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| TW521073B (en) | 1994-01-05 | 2003-02-21 | Hoechst Marion Roussel Inc | New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them |
| FR2716110B1 (fr) | 1994-02-16 | 1996-04-05 | Roussel Uclaf | Compositions cosmétiques ou pharmaceutiques comprenant des liposomes. |
| US5656651A (en) | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
| ES2300151T3 (es) | 1998-09-22 | 2008-06-01 | Astellas Pharma Inc. | Derivados de cianofenilo. |
| US6472415B1 (en) | 1998-12-18 | 2002-10-29 | Biophysica, Inc. | Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes |
| US6861432B2 (en) | 2001-11-23 | 2005-03-01 | Schering Aktiengesellschaft | Piperazine derivatives that destabilize androgen receptors |
| CA2482382A1 (en) | 2002-04-12 | 2003-10-23 | Pfizer Inc. | Pyrazole compounds as anti-inflammatory and analgesic agents |
| EP1656357A1 (en) | 2003-07-02 | 2006-05-17 | Merck & Co., Inc. | Oxazolidinone antibiotics and derivatives thereof |
| BRPI0414918A (pt) | 2003-09-30 | 2006-11-07 | Janssen Pharmaceutica Nv | compostos de benzoimidazola |
| WO2005061463A1 (en) | 2003-12-23 | 2005-07-07 | Astex Therapeutics Limited | Pyrazole derivatives as protein kinase modulators |
| WO2006013887A1 (ja) | 2004-08-03 | 2006-02-09 | Chugai Seiyaku Kabushiki Kaisha | 新規イミダゾリジン誘導体 |
| TW200621723A (en) | 2004-09-09 | 2006-07-01 | Chugai Pharmaceutical Co Ltd | Novel imidazolidine derivative and use thereof |
| RU2389721C2 (ru) | 2004-12-03 | 2010-05-20 | Ф.Хоффманн-Ля Рош Аг | 3-замещенные производные пиридина в качестве антагонистов гистаминовых н3 рецепторов |
| KR20240148945A (ko) * | 2005-05-13 | 2024-10-11 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 디아릴히단토인 화합물 |
| US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
| KR20160027254A (ko) | 2006-03-29 | 2016-03-09 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 디아릴티오히단토인 화합물 |
| JP5535925B2 (ja) | 2007-10-26 | 2014-07-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アンドロゲン受容体調節物質としてのジアリールヒダントイン化合物 |
| EP2242745A1 (de) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
-
2010
- 2010-08-19 TW TW099127804A patent/TW201111378A/zh unknown
- 2010-08-28 CA CA2773591A patent/CA2773591A1/en not_active Abandoned
- 2010-08-28 PH PH1/2012/500497A patent/PH12012500497A1/en unknown
- 2010-08-28 SG SG2012014262A patent/SG178919A1/en unknown
- 2010-08-28 CN CN2010800508678A patent/CN102639523A/zh active Pending
- 2010-08-28 BR BR112012005526A patent/BR112012005526A2/pt not_active Application Discontinuation
- 2010-08-28 KR KR1020127009224A patent/KR20120065396A/ko not_active Withdrawn
- 2010-08-28 EP EP10747836A patent/EP2475653A1/en not_active Withdrawn
- 2010-08-28 PE PE2012000315A patent/PE20121180A1/es not_active Application Discontinuation
- 2010-08-28 EA EA201200473A patent/EA201200473A1/ru unknown
- 2010-08-28 WO PCT/EP2010/005297 patent/WO2011029537A1/en not_active Ceased
- 2010-08-28 JP JP2012528249A patent/JP2013504523A/ja not_active Withdrawn
- 2010-08-28 AU AU2010294588A patent/AU2010294588A1/en not_active Abandoned
- 2010-08-28 IN IN2081DEN2012 patent/IN2012DN02081A/en unknown
- 2010-08-28 MX MX2012002977A patent/MX2012002977A/es active IP Right Grant
- 2010-08-28 US US13/394,536 patent/US20120251551A1/en not_active Abandoned
- 2010-08-28 NZ NZ598643A patent/NZ598643A/xx not_active IP Right Cessation
- 2010-09-08 UY UY0001032882A patent/UY32882A/es not_active Application Discontinuation
- 2010-09-10 AR ARP100103311A patent/AR078166A1/es unknown
-
2012
- 2012-02-29 IL IL218390A patent/IL218390A0/en unknown
- 2012-03-08 MA MA34666A patent/MA33566B1/fr unknown
- 2012-03-08 TN TNP2012000108A patent/TN2012000108A1/en unknown
- 2012-03-09 CO CO12041855A patent/CO6511228A2/es not_active Application Discontinuation
- 2012-03-09 EC ECSP12011716 patent/ECSP12011716A/es unknown
- 2012-03-09 CL CL2012000623A patent/CL2012000623A1/es unknown
- 2012-03-09 CR CR20120113A patent/CR20120113A/es unknown
- 2012-03-09 CU CU20120042A patent/CU20120042A7/es unknown
- 2012-03-09 DO DO2012000063A patent/DOP2012000063A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP12011716A (es) | 2012-04-30 |
| MX2012002977A (es) | 2012-04-30 |
| US20120251551A1 (en) | 2012-10-04 |
| CR20120113A (es) | 2012-05-02 |
| EP2475653A1 (en) | 2012-07-18 |
| NZ598643A (en) | 2013-10-25 |
| IN2012DN02081A (es) | 2015-08-21 |
| CU20120042A7 (es) | 2012-06-21 |
| JP2013504523A (ja) | 2013-02-07 |
| AU2010294588A1 (en) | 2012-04-05 |
| EA201200473A1 (ru) | 2012-10-30 |
| WO2011029537A1 (en) | 2011-03-17 |
| CL2012000623A1 (es) | 2012-09-14 |
| SG178919A1 (en) | 2012-04-27 |
| BR112012005526A2 (pt) | 2016-04-26 |
| TW201111378A (en) | 2011-04-01 |
| DOP2012000063A (es) | 2012-05-15 |
| KR20120065396A (ko) | 2012-06-20 |
| TN2012000108A1 (en) | 2013-09-19 |
| CO6511228A2 (es) | 2012-08-31 |
| CN102639523A (zh) | 2012-08-15 |
| UY32882A (es) | 2011-04-29 |
| CA2773591A1 (en) | 2011-03-17 |
| MA33566B1 (fr) | 2012-09-01 |
| IL218390A0 (en) | 2012-04-30 |
| PH12012500497A1 (en) | 2012-10-22 |
| PE20121180A1 (es) | 2012-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078166A1 (es) | (heteroarilmetil) tiohidantoinas sustituidas | |
| ES2490266T3 (es) | Derivados azacíclicos como inhibidores de HSL | |
| NI201100181A (es) | Análogos de isoxazol - 3 (2h ) -ona como agentes terapéuticos | |
| AR098912A1 (es) | Inhibidores de syk | |
| ES2524966T3 (es) | Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer | |
| ECSP088431A (es) | Derivados de pirazolo | |
| ES2669189T3 (es) | Compuestos de carbazol útiles como inhibidores del bromodominio | |
| CO6260017A2 (es) | Compuestos de oxazol, oxadiazol y tiadiazol utiles para el control de nematodos | |
| AR081859A1 (es) | Pirimidinas 2,4,6-trisustituidas, composiciones farmaceuticas que las comprenden y su uso en el tratamiento de tumores sensibles a la inhibicion de la cinasa atr | |
| AR088692A1 (es) | Derivados de 2-(1,2,3-triazol-2-il)benzamina y 3-(1,2,3-triazol-2-il)picolinamida | |
| DOP2007000014A (es) | Derivados de sulfonamidas, su preparacion y su aplicacion en terapeutica | |
| NZ629025A (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| UY31940A (es) | Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones | |
| CO6321238A2 (es) | Compuesto heterociclico con accion antagonista del glucagon | |
| AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
| CY1115637T1 (el) | Παραγων ενεργοποιησης για υποδοχεα που ενεργοποιειται απο πολλαπλασιαστη υπεροξυσωματος | |
| AR061520A1 (es) | Derivados de cinamoil-piperazina | |
| CO6251357A2 (es) | Nuevos derivados de acido azabifenilaminobenzoico | |
| ECSP088479A (es) | Derivados de oxadiazol | |
| AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
| CO6210701A2 (es) | Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-carboxilico | |
| PA8776401A1 (es) | Nuevos compuestos hetericiclicos nitrogenados, su preparación y su utilización como medicamentos antibacterianos | |
| CY1121626T1 (el) | Νεο παραγωγο υδροξαμικου οξεος ή αλας αυτου | |
| AR073821A1 (es) | Derivados de 2-amidotiadiazol, agonistas de los receptores s1p1 | |
| ECSP088805A (es) | 2-(piridin-2-il)-pirimidinas como fungicidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |